SOURCE: DNAPrint Genomics, Inc.

December 05, 2006 07:00 ET

DNAPrint Pharmaceuticals to Present at NYSSA Biotech/Specialty Pharma Conference

SARASOTA, FL -- (MARKET WIRE) -- December 5, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., will present an overview of the Company's wholly owned subsidiary DNAPrint Pharmaceuticals, Inc. to investors at the 10th Annual New York Society of Securities Analysts (NYSSA) Biotech/Specialty Pharma Conference on Tues., Dec. 12, 2006 at 1:40 p.m. Eastern time, at the Association's headquarters, 1177 Ave. of the Americas, in New York City.

About NYSSA

A not-for-profit educational organization, The New York Society of Securities Analysts (NYSSA) promotes awareness and understanding of securities analysis, investing, and the operation of the securities markets. Its members are recognized as ethical, knowledgeable investors and decision-makers. With more than 9,000 members, NYSSA is the largest of the more than 134 financial analyst societies worldwide that comprise the CFA Institute (http://www.cfainstitute.org).

About DNAPrint Genomics, Inc.


DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941-366-3400
    or
    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848